"description","uuid:ID","id","instanceType","name","rationale","label"
"The main design for the study","ce28dc68-9f64-4c5c-88f6-fad7319d134a","StudyDesign_1","StudyDesign","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.",""
